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Abstract  
This study investigates the rates of primary psychotic disorders (PPD) and substance induced 
psychotic disorders (SIPDs) in methamphetamine (MA) users accessing needle and syringe 
programs (NSPs). The aim was to determine if there are systematic differences in the 
characteristics of MA users with PPDs and SIPDs compared to those with no psychotic 
disorder. Participants were 198 MA users reporting use in the previous month. Diagnosis was 
determined using the Psychiatric Research Interview for DSM-IV Substance and Mental 
Disorders (PRISM-IV). Current psychiatric symptoms and substance use were also measured. 
Just over half (N=101) of participants met DSM-IV criteria for a lifetime psychotic disorder, 
including 81 (80%) with a SIPD and 20 (20%) with a PPD. Those with a younger age of 
onset of weekly MA use were at increased risk of a lifetime SIPD.  A current psychotic 
disorder was found in 62 (39%), comprising 49 SIPDs (79%) and 13 PPDs (21%). MA users 
with a current PPD were more likely to have received psychiatric treatment in the past month 
than those with a current SIPD, despite a similar level of psychotic symptom severity.  A high 
proportion of MA users accessing NSPs have psychotic disorders, the majority of which are 
substance-induced.  
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1.0 Introduction  
The relationship between methamphetamine (MA) use and psychotic phenomenon is well 
established. These symptoms typically involve persecutory delusions and hallucinations, 
which usually remit following cessation of MA use (Ali et al. 2010). Cross sectional studies 
have shown a link between recreational and regular MA use and psychotic symptoms, 
particularly among individuals with MA dependence (Hall et al. 1996, McKetin et al. 2008, 
McKetin et al. 2010). A 3 year prospective study of a treated sample of individuals with MA 
dependence found a 5-fold increase in the risk of the presence of psychotic symptoms during 
MA use relative to abstinence (McKetin et al. 2013). Evidence for a dose-dependent 
relationship between days MA use and the presence of psychotic symptoms was also found. 
The Fifth edition of the Diagnostic and Statistical Manual of Mental Disorders  
(DSM-5) defines a substance-induced psychotic disorder (SIPD) as the development of 
prominent delusions and/or hallucinations during or within a month of intoxication or 
withdrawal from psychotomimetic drugs such as MA and cannabis. These are distinct from 
primary psychotic disorders (PPDs) among substance users in which the psychotic symptoms 
(i) preceded the onset of substance use; (ii) persisted substantially after the cessation of 
severe intoxication or acute withdrawal; (iii) are substantially in excess of what would be 
expected given the type, amount or duration of substance use or (iv) there is a history of 
psychotic episodes that occurred independent of substance use (American Psychiatric 
Association. 2013).  
A growing number of studies have examined the rates of psychotic disorders among 
MA users.  A Norweigen study of 285 MA users admitted to two psychiatric hospitals, 
reported 9 (26%) out of 38 patients with a positive MA drug screen had a current MA 
induced psychotic disorder, with 55% of all diagnoses confirmed on the Mini-International 
Neuropsychiatric Interview (MINI) (Medhus et al. 2013). A study of 449 MA psychosis 
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patients who were admitted to a psychiatric hospital in Thailand between 2000 and 2001, 
found 16% had a current psychotic disorder on the MINI at 6-7 years follow up 
(Kittirattanapaiboon  et al. 2010).  
Only two studies have compared MA users with and without psychotic disorders. 
Chen et al., (2003) compared MA users (n=445; Taiwanese psychiatric hospital & detention 
centres) with a lifetime diagnosis of a MA-induced psychotic disorder (n=174; 39%; using 
the Diagnostic Interview for Genetic Studies) to those without (n=261; 59%). A younger age 
of first MA use, use of larger amounts of MA, the presence of schizoid/schizotypal 
personality traits and major depressive depression, alcohol dependence and antisocial 
personality disorder were associated with an increased risk of a lifetime MA-induced 
psychotic disorder. Those with a MA-induced psychotic disorder were also five times more 
likely to have a family history of schizophrenia than those without psychosis (Chen et al. 
2005). Glasner-Edwards et al., (2008) examined the outcomes of a treated sample of MA 
dependent individuals (n=526) with (n=68; 13%) and without (n=458; 86%) a lifetime history 
of  a psychotic disorder diagnosed at 3 years follow up on the MINI. The presence of a 
psychotic disorder impacted on psychiatric but not substance use outcomes, including the 
frequency of MA use. Those with a lifetime history of psychotic disorder had an elevated risk 
and frequency of psychiatric hospitalizations, lifetime suicide attempts, had more severe 
psychiatric symptoms and poorer medical, legal and employment outcomes at 3 years follow 
up.  
 It is difficult to draw conclusions about the rates or distinguishing features of 
psychotic disorders among MA users due to methodological differences in the research 
conducted to date. Research has varied in the MA inclusion criteria used, ranging from MA 
users (Chen et al. 2003) to individuals with a positive urine screen for MA (Medhus et al. 
2013), MA dependence  (Glasner-Edwards et al. 2008, Salo et al. 2011) or MA psychosis 
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only (Kittirattanapaiboon  et al. 2010). MA users have also been recruited from a variety 
settings including psychiatric hospitals (Chen et al. 2003, Medhus et al. 2013) 
(Kittirattanapaiboon  et al. 2010), detention centers (Chen et al. 2003)) and treatment settings 
for MA dependence (Glasner-Edwards et al. 2008). There are also variations in whether 
lifetime or current psychotic disorders (Glasner-Edwards et al. 2008, Kittirattanapaiboon  et 
al. 2010) versus MA induced psychotic disorders (Chen et al. 2003, Medhus et al. 2013) were 
reported as well as the timing of diagnostic assessments. All but one study used brief 
structured clinical interviews that do not differentiate between primary and substance-induced 
psychotic disorders (Chen et al. 2003, Glasner-Edwards et al. 2008, Kittirattanapaiboon  et al. 
2010, Medhus et al. 2013), despite the psychotomimetic effects of MA (McKetin et al. 2013). 
The only study which used the Structured Clinical Interview for DSM-IV (SCID) to 
differentiate primary from substance-induced psychotic disorders among a community 
sample of MA dependent adults (n=189) found 24% (n=45) had a lifetime substance induced 
psychotic disorders (SIPD) and 5% (n=9) had a lifetime primary psychotic disorder (PPD) 
(Salo et al. 2011). Research is yet to determine what proportion of MA users meet lifetime or 
current diagnostic criteria for a PPD or SIPD, or compare the characteristics, course and 
outcomes these diagnostic groups.   
This study (i) examines rates of DSM-IV lifetime and current SIPD and PPD 
psychotic disorders in a community sample of MA users using the Psychiatric Research 
Interview for DSM-IV Substance and Mental disorders (PRISM-IV), a well-validated 
structured clinical interview developed to differentiate primary from substance-induced 
psychosis disorders. This study also (ii) compares MA users with lifetime SIPD, PPDs and no 
psychotic disorder on demographic and lifetime clinical and substance use variables (iii) 
identifies which of these variables increase the risk of a lifetime SIPD and PPD relative to no 
psychotic disorder and (iv) compares MA users with a current PPD and SIPD on 
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demographic and recent clinical and substance use variables.  
 
2.0 Method  
2.1 Participants and procedure 
Current MA users (n=198) were recruited from inner-city needle syringe programs (NSPs) in 
three Australian cities, which provide free needles and syringes. The sample consisted of 120 
males (61%) and 78 (39%) females, with an average age was 31.65 (SD=8.18) years.. 
Participants were required to have used MA in the previous month and to identify MA as 
their primary drug of choice. The majority (91%, n=172/198) of participants had injected MA 
in their lifetime and 84% (n=136/177) reported current injecting MA use at one month follow 
up. This is the most common method of MA use in Australia, with over two-thirds of 
treatment seeking MA users reporting injecting use (McKetin et al. 2012). 
  Following collection of injecting materials, NSP clients were routinely asked their 
age, drug of choice and postcode. Those who indicated MA was their primary drug were 
invited to participate in a participating in a 12 month prospective study examining the 
relationship between MA and psychotic symptoms. Baseline interviews were conducted in 
interview rooms at the NSP or in a location convenient to the participant. The interviews 
were administered by researchers with postgraduate qualifications in psychology.  The 
diagnostic interview was delayed if the participant had used MA in the past 24 hours to 
ensure the reliability of the interview was not affected by acute MA intoxication. The TLFB 
was used to verify the most recent occasion of MA use. The study received approval from 
participating Ethics Committees. Participants received AUD$10 as compensation for their 
time.   
 
2.2 Measures    
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2.2.1 Structured clinical diagnostic interview  
Sections 2 and 8 of the PRISM-IV Version 6 were administered to provide lifetime and 
current DSM-IV diagnoses of SIPD and PPD (Hasin et al. 1996). The PRISM achieves this 
by: i) obtaining a lifetime and recent (past 12 months) timeline of the onset and patterns 
(chronic intoxication/binge use; abstinence/minimal use) of substance use; ii) determining the 
temporal relationship of psychotic symptoms and substance use, and iii) providing detailed 
guidelines for differentiating primary disorders from SIPD and from the expected effects of 
intoxication and withdrawal. The PRISM also requires a 1-month active phase of two (or 
more) psychotic symptoms for a diagnosis of a PPD or a SIPD to be made. For a SIPD this 
active phase must occur entirely during a period of heavy substance use or within the first 
four weeks after cessation of use. The psychotic symptoms must also be greater than the 
expected effects of substance intoxication and/or withdrawal. A PPD is differentiated from a 
SIPD by the presence of an active phase which (i) commences 2 weeks before heavy 
substance use or persists for more than a month after abstinence or occasional substance use 
(when the expected effects of intoxication or withdrawal could not have occurred).  
The PRISM reliably differentiates between PPD and SIPD (kappa=0.70-0.83) with a 
high level of test-retest reliability (Torrens et al. 2004). PRISM diagnoses for SIPD and 
schizophrenia have significantly better concordance with diagnoses derived by mental health 
professionals using longitudinal, expert, all data (LEAD) criteria and than the SCID (Torrens 
et al. 2004). To reduce the length of the assessment session, the major depressive and manic 
episode modules of the MINI (Lecrubier et al. 1997) were administered, rather than the 
equivalent PRISM modules. The researchers were trained in the use of the PRISM by LH, an 
accredited user.   
 
2.2.2 Substance use 
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The frequency of drug and alcohol use in the past 4 weeks was assessed using the calendar-
based Timeline Follow Back method (TLFB; Fals Stewart et al. 2000). The TLFB has good 
test-retest reliability (r ≥ .79) as well as convergent and divergent validity with other 
measures of substance use. The severity of MA, cannabis, heroin and alcohol dependence in 
the past year was assessed using the Severity of Dependence Scale (SDS; Gossop et al., 
1995). The SDS is a well validated measure of the severity of dependence that can be applied 
across various drug types (Gossop et al. 1995). It includes 5 items rated on a 4 point likert 
scale, yielding a score from 0 to 15, with higher scores reflecting more severe dependence. 
Cut-off scores of > 4 and > 3 are equivalent to DSM-IV diagnoses of MA and cannabis 
dependence respectively (Topp and Mattick 1997, Swift et al. 1998).  Information on the age 
of onset (lifetime and regular (weekly) of alcohol and drug use was collected from the 
PRISM.   
 
2.2.3 Clinical measures 
The 24-item Brief Psychiatric Rating Scale (BPRS; Lukoff et al. 1986) is a clinician-rated 
measure of  the severity of positive, negative, manic-excitement and depression/anxiety 
symptoms in the last month, rated on a 7 point scale from 1 (not present) to 7 (extremely 
severe) scale. This measure has well established reliability and validity in first episode 
psychosis and provides a measure of four subscales (positive, negative, manic-excitement, 
depression-anxiety symptoms) (Ventura et al. 2000). The principle researchers (LH, SD, RM) 
attended a BPRS training workshop provided by Professor Peter Ventura. They subsequently 
trained and supervised the research staff to ensure ongoing reliability. Out of the 2,019 
interviews conducted during the 12 month study, 142 (7.03%) were rated for inter-rater 
reliability purposes. The intraclass correlation coefficient for the total BPRS score was .97. 
Information on the patient’s personal and family history of schizophrenia and other mental 
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health disorders was obtained by asking if they or an immediate member of their family had a 
diagnosis of the following: schizophrenia, SIPD, bipolar disorder, anxiety or depression. 
 
2.3 Analysis    
MA users with a lifetime DSM-IV PPD, SIPD or no psychotic disorder were first compared 
on demographic and lifetime substance use and clinical variables, using Chi squares for 
categorical data and ANOVAs for continuous data. A multinomial logistic regression analysis 
was then conducted to identify which of the potential predictors identified in the previous 
analyses, differentiated MA users with lifetime SIPD and PPDs from those with no psychotic 
disorder. Age and gender were included in this analysis to control for key demographic 
characteristics. Family history of psychosis was also included as it has been associated with 
psychosis among MA users (Chen et al. 2003). Other clinical variables (e.g. personal 
psychiatric history) were not included in this analysis, given the adverse impact of zero or 
small cell sizes in the no psychotic disorder group on parameter estimates in the logistic 
models (Hosmer and Lemeshow 2005). A sub-analysis was conducted to compare MA users 
with a current PPD versus SIPD on demographic and recent substance use and clinical 
variables. All analyses used SPSS Version 22.0 software (SPSS Inc, Chicago, Ill) and 
statistical significance was determined using the .05 level and 2-tailed tests of significance.  
 
3.0 Results   
3.1 Rates of psychotic disorders in MA users 
Figure 1 displays the rates of DSM-IV psychotic disorders relative to no psychotic disorder 
(no lifetime history of any psychotic disorder), and lifetime and current PPDs and SIPDs 
diagnosed using the PRISM. Just over 50% (n=101) of the sample had a lifetime or current 
psychotic disorder, including 81 (80%) with a lifetime or current SIPD and 20 (20%) with a 
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lifetime or current PPD. A higher proportion of current and lifetime psychotic disorders were 
substance-induced rather than primary.  
_______________ 
Insert Figure 1 about here 
_______________ 
 
3.2 Comparisons of MA users with a lifetime SIPD, PPD and no psychotic disorder on 
demographic and lifetime substance use and clinical variables. 
There were no significant between-group differences on any demographic variable (See 
Table 1). Participants with a PPD were most likely to have been diagnosed with 
schizophrenia (χ2[2, n=197]=46.66, p<0.001) or bipolar disorder (χ2[2, n=197]=9.64, p= 
0.008) in their lifetime (see Table 2). They had also presented to emergency departments or 
psychiatric hospitals on more occasions (F(2, 144)=11.16, p<0.001) than either the SIPD or 
no psychotic disorder group, and were more likely to have taken psychiatric medication in 
their lifetime (χ2[2, n=196]=15.46, p<0.001).  Significant between-group differences in the 
age of onset of first (F(2, 197)=3.58, p=0.030) and regular (weekly) (F(2, 191)=5.81, 
p=0.004) MA use were found (See Table 2). Post hoc tests indicated that participants with a 
lifetime SIPD had significantly younger age of onset of first and regular MA use than those 
without a psychotic disorder. There was no difference in the age of onset of MA use between 
the PPD and SIPD groups.  
 
_______________ 
Insert Tables 1 & 2 about here 
_______________ 
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3.3 Prediction of lifetime SIPD and PPDs relative to no psychotic disorder among MA 
users 
A multinomial logistic regression with simultaneous entry was conducted to determine which 
demographic and substance use variables differentiated MA users with a lifetime SIPD or 
PPD from those with no history of a psychotic disorder (Table 3). Since age of onset of 
regular MA use was the only substance use variable that differentiated between these 
diagnostic groups, it was the only other predictor entered into the equation along with age, 
gender and family history of schizophrenia  (Table 3). The age when regular MA use started 
differentiated SIPD participants from those with no psychotic disorder, accounting for 8.8% 
(Nagelkerke R squared) of the variance in diagnostic status, with 52.7% diagnostic accuracy. 
Each one-year delay in the age of onset of weekly MA use decreased the odds of a SIPD by 
.94. No predictors differentiated participants with a PPD from those without psychotic 
disorder.  
_______________ 
Insert Table 3 about here 
_______________ 
3.4 Comparison of MA users with a current SIPD and PPD on demographic and recent 
substance use and clinical variables. 
Participants with a current SIPD and PPD did not differ on any demographic variable (See 
Table 1). Participants with a current PPD were more likely to have presented to an emergency 
department or psychiatric hospital (χ2[1,n=59]=9.07, p=0.003) and to have taken psychiatric 
medication in the past month (χ2[1,n=60]=7.12, p=0.008), including antipsychotics 
(χ2[1,n=61]=6.23, p=0.013) (see Table 4). No significant between-group differences were 
found on the BPRS positive, negative, manic-excitement or depression-anxiety subscales or 
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the total score. The current SIPD and PPD groups did not differ on the frequency of MA, 
cannabis, alcohol or heroin use in the past 30 or 7 days. Sixty-three percent (N=39) MA users 
with a current psychotic disorder had MA dependence on the SDS. The same proportion had 
cannabis dependence (N=39), and 40% (N=25) had both MA and cannabis dependence. No 
significant differences in the rates of MA, cannabis or MA/cannabis dependence combined   
were found between the SIPD and PPD groups.  
 
_______________ 
Insert Table 4 about here 
_______________ 
 
4.0 Discussion 
This is the first study to examine rates of lifetime and current SIPD and PPD disorders in a 
large sample of MA users, using a structured clinical interview designed to differentiate 
between these disorders (the PRISM). Just over half (N=102; 51%) of this sample of MA 
users accessing NSPs had a DSM-IV lifetime psychotic disorder, the majority of which were 
substance-induced (80%). Only 10% of the sample had PPDs. This rate of lifetime psychotic 
disorders is higher than those reported in previous research among MA users admitted to 
psychiatric hospitals (13-39%) (Chen et al. 2003, Glasner-Edwards et al. 2008, Medhus et al. 
2013) and MA dependent adults (27%) (Salo et al. 2011). This may reflect the fact that the 
current sample were injecting MA users, using a more potent method of MA administration 
that is associated with more frequent MA use (Hall and Hando 1994) and increased risk of 
psychotic symptoms (McKetin et al. 2013). Nevertheless, a similar proportion of SIPDs 
(83%) relative to PPDs (17%) were found in the only other study which has differentiated 
primary from substance-induced psychotic disorders (using the SCID) among MA dependent 
adults (Salo et al. 2011). This highlights the importance of differentiating SIPDs from PPDs 
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in MA users and suggests previous research may have underestimated the rates of psychotic 
disorders in MA users. Prospective research is required to examine the course and stability of 
PPD and SIPDs in MA users, as MA users with a SIPD may develop a PPD, and those with a 
PPD may develop a SIPD or have another PPD over time. 
Increased risk of a lifetime SIPD relative to no psychotic disorder was associated with 
a younger age of onset of regular MA use but not a family history of schizophrenia in the 
logistic regression. Each one-year delay in the onset of regular (weekly) MA use decreased 
the risk of a lifetime SIPD by a factor of .94. This is partially consistent with Chen’s (2003) 
finding that age of first MA use and a family history of schizophrenia predicted lifetime MA-
induced psychosis. The use of the DIGS as a diagnostic measure and exclusion of MA users 
with a history of psychosis in the Chen study may have contributed to this variation in 
findings. Neither the age of onset of regular MA use nor a family history of schizophrenia  
differentiated MA users with a lifetime PPD from those without a psychotic disorder. 
However, the exclusion of MA users personal psychiatric history from this analysis would 
have contributed to these results. MA users with a lifetime PPD were more likely to have a 
history of schizophrenia/bipolar disorder and received psychiatric treatment than those with 
no psychotic disorders in the group comparisons.  
MA users with current SIPDs and PPDs were then compared. No significant 
differences in recent substance use or psychiatric symptom severity were found.  This may be 
associated with the small number of MA users with a current PPD (n=13) in the sample. 
Nevertheless, the frequency of recent MA use was almost 50% higher in the SIPD group. 
Previous research comparing first episode psychosis samples with SIPD and PPDS has 
reported more frequent substance use in the SIPD group (Caton et al. 2005, Fraser et al. 
2012), but further research among MA users is needed. Those with a current PPD were more 
likely to have accessed psychiatric treatment (including antipsychotic medication) in the past 
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month than those with a current SIPD. This indicates MA users with current SIPD were 
unlikely to seek or receive psychiatric treatment despite the presence of marked psychiatric 
symptoms comparable to those with a PPD, as no differences in psychiatric symptom severity 
between the two groups were found. Whether this is due to the PPD group being more likely 
to seek or receive treatment, or the SIPD group being less likely to seek treatment because 
they consider their symptoms to be substance-induced is unknown.  
The cross-sectional nature of this study limits the conclusions that can be made 
regarding the impact of MA and other substance use on the onset, course or stability of 
diagnoses of SIPD and PPDs over time. While the sample size of MA users was large, it is 
not representative of MA users as participants were recruited from an NSP and had high rates 
of injecting MA use. Further research examining the rates and characteristics of SIPD and 
PPDs among MA users using other routes of MA use, from the community and treatment-
based services is warranted. Although the SIPD/PPD groups did not differ on the SDS in the 
severity of MA dependence, future research is required to determine the impact of the 
presence of DSM-5 MA dependence on the rates and characteristics of these disorders in MA 
users. The use of the PRISM, a highly reliable and valid diagnostic interview for 
differentiating SIPD from PPD in substance users is a major strength of the study. For a 
diagnosis of a PPD or a SIPD to be made, MA users were required to have an active phase of 
two (or more) psychotic symptoms present for at least a month, which were more severe than 
the expected effects of substance intoxication and/or withdrawal. No significant differences 
in BPRS symptoms or the frequency of MA, alcohol or other illicit drugs used in the 7 days 
prior to the interview were found between the SIPD and PPD groups. Participants were 
required to abstain from MA use in the 24 hours prior to the PRISM interview, to ensure the 
reliability of the interview was not affected by acute MA intoxication. Together these 
findings indicate that current results are unlikely to be due to the psychotomimetic effects of 
15 
MA intoxication or withdrawal. Finally, while a small proportion of MA users had a lifetime 
(n=20) and current PPD (n=13), the overall sample size was adequate for the analyses 
conducted (Hosmer and Lemeshow 2005). 
  Results indicating that almost a third of MA users accessing NSPs had a current 
psychotic disorder are alarming, as these services are not adequately equipped to manage 
individuals with acute psychotic disorders. There is an urgent need for NSPs to screen for 
psychotic symptoms in MA users, and work closely with addiction services and mental health 
services to ensure these have access to appropriate clinical care and treatment (Colfax et al. 
2010). It is imperative that MA users with PPD are actively engaged in such care, due to the 
risk of relapse and other poor outcomes.  The high rates of untreated SIPD among MA users, 
highlights the need for effective public health campaigns and early intervention programs 
highlighting the risks of psychotic symptoms and disorders in MA users.  
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Figure 1: Rates of current and lifetime psychotic disorders in MA users 
  
MA users n=198 
 
Psychotic Disorder 
n=101 (51%) 
 
 
No Psychotic 
Disorder 
n=97 (49%) 
 
Current n=62 (61%)  
 
SIPD n=49 (79%) 
PPD n=13 (21%) 
Lifetime n=39 (39%) 
 
SIPD n=32 (82%) 
PPD n=7 (18%) 
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Table 1. Comparisons of MA users with lifetime SIPD, PPD and no psychotic disorders and 
current SIPD versus PPDs on demographic variables.   
 
Variable 
 
Lifetime SIPD, PPD versus no psychotic 
disorder 
Current SIPD versus PPD  
 
 
No 
psychotic 
disorder 
(n=97) 
PPD 
(n=20) 
SIPD 
(n=81) 
p PPD 
(n=13) 
SIPD 
(n=49) 
p 
Gender, n (%)    
  Male 
  Female 
 
55 (57) 
41 (42) 
 
12 (60) 
8 (40) 
 
53 (65) 
28 (35) 
 
 
.540 
 
9 (69) 
4 (31) 
 
34 (69) 
15 (31) 
 
 
.991 
 
Age, M (SD) 
 
32.95 
(8.80) 
 
30.25 
(8.75) 
 
30.44 
(7.05) 
 
.092 
 
30.54 
(8.97) 
 
30.36 
(6.99) 
 
.941 
Rel’ship, n (%)  
  Single 
  Partner  
 
78 (80) 
18 (19) 
 
17 (85) 
3 (15) 
 
56 (69) 
25 (31) 
 
 
.107 
 
11 (85) 
2 (15) 
 
34 (69) 
15 (31) 
 
 
.274 
 
Education 
  < Year 12 
 
 
55 (57) 
 
 
11 (55) 
 
 
41 (51) 
 
 
.626 
 
 
7 (54) 
 
 
25 (51) 
 
 
.856 
 
Unemployed 
 
56 (58) 
 
9 (45) 
 
44 (54) 
 
.572 
 
7 (54) 
 
28 (57) 
 
.831 
 
Homeless 
 
2 (2) 
 
0 
 
4 (5) 
 
.379 
 
0 
 
4 (8) 
 
.287 
 
Living   
  Alone 
  Others  
 
 
14 (14) 
83 (86) 
 
 
2 (10) 
18 (90) 
 
 
14 (17) 
67 (83) 
 
 
 
.691 
 
 
0 
13 (100) 
 
 
8 (16) 
41 (84) 
 
 
 
.119 
 
Ethnicity 
  Caucasian 
  Aboriginal 
  Other 
 
 
84 (87) 
5 (5) 
8 (8) 
 
 
15 (75)  
2 (10) 
3 (15) 
 
 
66 (81) 
4 (5) 
11 (14) 
 
 
 
 
.635 
 
 
 
9 (69)  
2 (15) 
2 (15) 
 
 
41 (84) 
3 (6) 
5 (10) 
 
 
 
 
.449 
 
Note: Rel’ship: Relationships 
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Table 2. Comparisons of MA users with lifetime SIPD, PPD and no psychotic disorder on 
lifetime substance use and clinical variables 
 
Variable  
 
No psychotic 
disorder   
(n =97) 
PPD  
(n=20) 
SIPD  
(n=81) 
p 
Substance use, M (SD) 
  Age of first use 
    MA 
    Alcohol 
    Cannabis 
  Age of onset weekly use 
    MA 
    Alcohol 
    Cannabis 
 
 
20.75 (7.45) 
14.16 (3.60) 
15.44 (4.88) 
 
24.03 (8.32) 
16.72 (3.68) 
16.88 (6.13) 
 
 
 
18.70 (4.80) 
12.91 (2.64) 
13.87 (2.16) 
 
23.15 (5.69) 
16.11 (2.97) 
16.60 (4.66) 
 
 
 
18.33 (4.63) 
13.38 (2.63) 
14.43 (2.53) 
 
20.26 (6.37) 
16.67 (5.18) 
15.59 (3.94) 
 
 
 
.030 
.135 
.112 
 
.004 
.857 
.294 
Family history, n (%) 
  Schizophrenia 
  Bipolar 
  Depression   
  Anxiety 
 
12 (12) 
7 (7) 
31 (32) 
12 (12) 
 
3 (23) 
1 (8) 
4 (31) 
2 (15) 
 
10 (20) 
6 (12) 
15 (31) 
13 (27) 
 
.291 
.506 
.979 
.057 
Psychiatric history*, n (%)    
  Schizophrenia 
  Bipolar 
  Depression 
  Anxiety 
  SIPD 
 
0 
5 (5) 
34 (35) 
12 (12) 
3 (3) 
 
8 (40) 
5 (25) 
9 (45) 
3 (15) 
1 (5)  
 
4 (5) 
5 (6) 
31 (39) 
14 (18) 
8 (10) 
 
< .001 
.008 
.667 
.631 
.157 
Hospital admissions, M (SD)   
   Total number 
Psychiatric medication, n (%)  
    Any in lifetime  
    Antipsychotic  
 
.26 (1.27) 
 
45 (46) 
3 (3) 
 
2.71 (4.78) 
 
18 (95) 
2 (10) 
 
.41 (.96) 
 
47 (59) 
6 (7) 
 
< .001 
 
< .001 
.301 
Note: Psychiatric history*: based on patient self report  
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Table 3. Multivariate prediction of lifetime PPD and SIPD among MA users relative to no 
psychotic disorder, by selected demographic and substance use variables  
 
 PPD (n=20) c.f. no psychotic 
disorder 
SIPD (n=81) c.f. no psychotic 
disorder 
Variables B (S.E) OR 
(95% CI) 
p B (S.E) OR (95% CI) p 
Age 
Male gender 
Family history of 
schizophrenia 
 
Age onset regular 
MA use 
-.05 (.04) 
 
.27 (.53) 
 
 
-.60 (.66) 
 
.03(.05) 
.96 (.88-1.04) 
 
1.30 (.46-3.69) 
 
 
.55 (.15-2.02)  
 
1.03(.94-1.12)  
 
.28 
 
.62 
 
 
.37 
 
.55 
-.02 (.02) 
 
.38 (.34) 
 
 
-.60(.44) 
 
-.06(.03) 
.98 (.94-1.03) 
 
1.46 (.75-2.84) 
 
 
.55 (.23-1.31) 
 
.94 (.89-.99) 
.48 
 
.27 
 
 
.17 
 
.04 
 
Note: Reference group: No psychotic disorder 
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Table 4. Comparison of MA users with current SIPD and PPD on current  
clinical and substance use variables  
 
Variable M(SD) PPD 
(n=13) 
SIPD 
(n=49) 
p 
Meds (past month), n (%) 
  Any 
  Antipsychotics 
 
8 (62) 
4 (31) 
 
11 (22) 
3 (6) 
 
.008 
.013 
Hospital admission, n (%) 
  Past month 
 
4 (31) 
 
2 (4) 
 
.003 
BPRS, M (SD) 
  Positive (5-35) 
  Negative (4-28) 
  Mania (6-42) 
  Depression-anxiety (4-28) 
  Total score 
 
9.92 (4.77) 
6.23 (2.31) 
10.00 (3.72) 
12.08 (5.66) 
43.33 (9.55) 
 
 
8.58 (3.71) 
5.91 (1.94) 
11.25 (5.62) 
11.88 (4.37) 
45.23 (13.38) 
 
 
.282 
.618 
.471 
.891 
.648 
TLFB – 30 days, M (SD) 
  MA 
  Alcohol 
    Drinks/day 
  Cannabis 
  Heroin 
 TLFB – 7 days, M (SD) 
  MA 
  Alcohol 
  Cannabis 
  Heroin 
   
 
8.39 (8.81) 
5.92 (6.47) 
4.27 (4.05)  
12.39 (12.12)  
.08 (.28)  
 
1.85 (2.23) 
1.62 (1.66) 
3.23 (2.80) 
.08 (.28) 
 
12.38 (10.06) 
8.43 (9.30) 
8.51 (15.11) 
16.54 (13.76) 
.71 (4.36) 
 
2.90 (2.50) 
1.92 (2.12) 
3.96 (3.24) 
.15 (1.01) 
 
 
.199 
.364 
.323 
.299 
.606 
 
.176 
.638 
.431 
.810 
 
SDS, Total score, M (SD)  
  MA 
  Alcohol 
  Cannabis  
  Heroin 
SDS Dependence, n (%) 
  MA  
  Cannabis    
  MA & cannabis 
 
5.00 (4.74) 
1.53 (2.67) 
4.08 (4.08) 
.15 (.55) 
 
6 (46) 
7 (54) 
3 (33) 
 
6.47 (4.22) 
4.11 (.60) 
4.87 (4.35) 
0  
 
33 (67) 
32 (54) 
22 (45) 
 
.284 
.185 
.557 
.337 
 
.160 
.447 
.154   
Notes: Meds: medication; BPRS: Brief Psychiatric Rating Scale; TLFB: Timeline follow 
back; SDS: Severity of Dependence Scale   
 
 
 
 
 
 
